Bio
Dec 12, 2023Oncusp's CDH6
Dec 05, 2023ADC Cleavable Linker: Classification and Mechanism of Action
Nov 29, 2023The ADC Technology Market is projected to grow at a CAGR of ~12% till 2035, claims Roots Analysis
Nov 23, 2023Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
Nov 16, 2023-
Bio
GUANGZHOU, China, Aug. 12, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutic
-
Oncusp's CDH6
Oncusp's CDH6-targeting ADC CUSP-06 cleared to enter clinic for solid tumors | BioWorld
-
ADC Cleavable Linker: Classification and Mechanism of Action
ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker play
-
The ADC Technology Market is projected to grow at a CAGR of ~12% till 2035, claims Roots Analysis
News provided by 23 Aug, 2023, 10:10 ET Share this article With the rising demand for more efficient and homogenous anti
-
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
News provided by 28 Aug, 2023, 04:30 ET Share this article CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, A
-
How Linker Technology Is Driving ADC Development
By Tyler Menichiello, contributing editor If you’re still not excited about antibody drug conjugates (ADC), “there’s an
-
Lilly signs up Verve to take on Novartis and Amgen
A month after signing a collaboration with Scribe, Lilly is putting another bet on in vivo gene editing. This time the p
-
ABO genotype alters the gut microbiota by regulating GalNAc levels in pigs
Nature volume 606, pages 358–367 (2022)Cite this article 22k Accesses 34 Citations 91 Altmetric Metrics details The comp
-
Discussion of Support Issue of Biological Sequence Claims from an Invalidation Case
Discussion of Support Issue of Biological Sequence Claims from an Invalidation Case - Lexology
-
Role of mucin glycosylation in the gut microbiota
Scientific Reports volume 13, Article number: 13982 (2023) Cite this article 97 Accesses 11 Altmetric Metrics details Al
-
Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 -August 16,
-
Nedosiran Emerging Drug Insight and Market Forecasts, 2032: Focus on 7 Major Markets
Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Nedosiran Emerging Drug Insight and Market Forecast - 2032" drug pipeline